Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements

Intergroupe Francophone de Cancerologie Thoracique318 enrolled

Overview

Description of clinical and anatomical features and long-term follow-up for patients with ALK rearrangement and treated by crizotinib

Several French studies on crizotinib have been conducted in recent years. These are not only patients treated in the PROFILE 1005 and 1007 clinical studies but also patients who have been treated with crizotinib in the named patient ATU followed by the cohort ATU (Expended Access Cohort). Under the ATU program and according to ATU regulations, a limited set of data is collected and furthermore the follow up is stopped as soon as the ATU program closes. Thus it is not possible to have access to long term data and post progression data. Our project is to collect data from the patients from the ATU program (named patient and cohort) and if possible patients treated after the marketing of crizotinib, before, during and after crizotinib therapy. Centers selected for this observational study will be those of the IFCT network that took part in the ATU program. This will allow an accurate analysis of crizotinib therapy under "real life" conditions. It should be emphasized that this information is generally neither available from clinical trials nor from ATU programs.

Study Type

OBSERVATIONAL

Enrollment

318

Conditions

Non-small Cell Lung Cancer Anaplastic Lymphoma Kinase Gene Mutation

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient must have locally advanced or metastatic NSCLC (Stage IIIb or Stage IV by AJCC 7th.) with positive ALK determined by IHC and/or FISH. * Patient who received crizotinib on an expanded access basis (compassionate use) (ATU) due to their inability to meet eligibility criteria for on-going recruiting trials, inability to participate in other clinical trials (e.g., poor performance status, lack of geographic proximity), or because other medical interventions are not considered appropriate or acceptable * Patient who received marketed crizotinib as a result of the standard care of metastatic NSCLC (Stage IIIb or Stage IV by AJCC 7th.) with positive ALK will also be eligible. * Patient was able to swallow capsules and had no surgical or anatomical condition that precluded the patient from swallowing and absorbing oral medications on an ongoing basis. * Patient has taken at least 1 week of treatment Exclusion Criteria: * Patient included in a crizotinib clinical trial * Patient with known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.

Locations (63)

Outcomes

Primary Outcomes

overall survival

overall survival post-progression on crizotinib

Time frame: 5 years

Secondary Outcomes

rare and severe complications of crizotinib therapy

Incidence of rare and severe complications of crizotinib therapy: hepatotoxicity, interstitial pneumonitis, diastolic heart failure

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Agen - CH

Agen, France

Angers - CHU

Angers, France

Angoulême - CH

Angoulême, France

Annecy - CH

Annecy, France

Avignon - Institut Sainte-Catherine

Avignon, France

CHU Besancon - Pneumologie

Besançon, France

Bordeaux - Clinique Saint Augustin

Bordeaux, France

Boulogne - Hôpital Ambroise Paré

Boulogne, France

Brest - Hôpital du Morvan

Brest, France

CH de Cannes

Cannes, France

...and 53 more locations